Indaptus Therapeutics, Inc.
INDP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001857044
No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.15M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Indaptus Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 18 | 18 | 0 |
| Shares | 567.2K | 576.6K | +9.39K (+1.7%) |
| Value | $1.22M | $838.5K | −$384.5K (−31.4%) |
New holders (2)
Institutions that held Indaptus Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 14,495 | $20.9K | 0.00% |
| Bank of America Corp | 11 | $16 | 0.00% |
Sold out (2)
Institutions that held Indaptus Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Citadel Advisors LLC | 10,895 | $24.0K |
| Steward Partners Investment Advisory, LLC | 28 | $0 |